Sage Therapeutics, Inc. (SAGE) Reaches $158.77 After 8.00% Down Move; McKesson (MCK) Covered By 12 Bulls

February 22, 2018 - By Vivian Currie

The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) is a huge mover today! The stock decreased 3.10% or $5.086 during the last trading session, reaching $158.774. About 324,803 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 116.45% since February 22, 2017 and is uptrending. It has outperformed by 99.75% the S&P500.The move comes after 5 months negative chart setup for the $7.23B company. It was reported on Feb, 22 by Barchart.com. We have $146.07 PT which if reached, will make NASDAQ:SAGE worth $578.08 million less.

Among 22 analysts covering McKesson Corporation (NYSE:MCK), 12 have Buy rating, 1 Sell and 9 Hold. Therefore 55% are positive. McKesson Corporation had 79 analyst reports since July 31, 2015 according to SRatingsIntel. The company was initiated on Tuesday, April 4 by Needham. The stock of McKesson Corporation (NYSE:MCK) earned “Buy” rating by Needham on Tuesday, October 24. As per Friday, January 15, the company rating was maintained by Mizuho. The firm earned “Neutral” rating on Tuesday, June 7 by Mizuho. Mizuho maintained it with “Neutral” rating and $197 target in Thursday, August 11 report. The firm has “Hold” rating by Mizuho given on Wednesday, January 24. The rating was initiated by UBS on Thursday, October 6 with “Neutral”. Deutsche Bank downgraded the shares of MCK in report on Friday, October 28 to “Hold” rating. The stock has “Hold” rating by Mizuho on Tuesday, May 30. Jefferies maintained McKesson Corporation (NYSE:MCK) rating on Wednesday, October 18. Jefferies has “Hold” rating and $165.0 target. See McKesson Corporation (NYSE:MCK) latest ratings:




02/02/2018 Broker: Needham Rating: Buy New Target: $185.0 Maintain
01/02/2018 Broker: RBC Capital Markets Rating: Hold New Target: $186.0 Maintain
01/02/2018 Broker: Mizuho Rating: Hold New Target: $179.0 Maintain
24/01/2018 Broker: Mizuho Rating: Hold New Target: $186.0 Maintain
24/01/2018 Broker: Jefferies Old Rating: Hold New Rating: Buy Upgrade
17/01/2018 Broker: Robert W. Baird Rating: Buy New Target: $200.0 Maintain
05/01/2018 Broker: Evercore Rating: Outperform New Target: $179 Initiates Coverage On
18/12/2017 Broker: Credit Suisse Rating: Sell New Target: $130.0 Downgrade
04/12/2017 Broker: Deutsche Bank Rating: Buy New Target: $175 Initiates Coverage On
09/11/2017 Broker: Credit Suisse Rating: Sell New Target: $130.0 Maintain

Since December 14, 2017, it had 0 insider buys, and 2 selling transactions for $17.36 million activity. Kanes Stephen sold $7.80M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) on Wednesday, January 10. Robichaud Albert also sold $9.57 million worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) shares.

Investors sentiment increased to 1.21 in Q3 2017. Its up 0.23, from 0.98 in 2017Q2. It is positive, as 33 investors sold Sage Therapeutics, Inc. shares while 43 reduced holdings. 28 funds opened positions while 64 raised stakes. 38.55 million shares or 3.62% more from 37.20 million shares in 2017Q2 were reported. Citadel Ltd Llc holds 0.01% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 108,200 shares. Prudential Fincl owns 3,818 shares for 0% of their portfolio. Essex Company Limited Company has invested 0.06% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Cubist Systematic Strategies Ltd Com holds 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE) or 1,052 shares. American Gp Inc invested 0.01% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Jabre Cap Prtnrs Sa holds 0.07% or 6,000 shares. Suffolk Cap Management Limited Liability reported 0.13% stake. Parametric Associates Limited holds 0% or 21,697 shares. Invesco Limited stated it has 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Paloma Prtn Mngmt holds 4,290 shares. Bessemer Gru, New Jersey-based fund reported 2,263 shares. Tower Rech Ltd Liability Corp (Trc) holds 0.03% in Sage Therapeutics, Inc. (NASDAQ:SAGE) or 5,525 shares. Westpac has invested 0.06% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Jane Street Grp Incorporated Limited Liability Corp holds 13,118 shares. Wells Fargo Mn holds 0% or 104,016 shares in its portfolio.

Among 17 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 15 have Buy rating, 0 Sell and 2 Hold. Therefore 88% are positive. SAGE Therapeutics has $203.0 highest and $18 lowest target. $120.73’s average target is -23.96% below currents $158.774 stock price. SAGE Therapeutics had 52 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was maintained by Stifel Nicolaus on Thursday, December 7 with “Buy”. The company was maintained on Thursday, November 2 by Stifel Nicolaus. The rating was maintained by RBC Capital Markets with “Buy” on Monday, October 16. The firm has “Buy” rating by Chardan Capital Markets given on Thursday, December 7. Bank of America maintained it with “Buy” rating and $101 target in Thursday, November 16 report. The company was maintained on Thursday, September 3 by JP Morgan. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Buy” rating given on Thursday, October 19 by SunTrust. On Thursday, December 7 the stock rating was maintained by BMO Capital Markets with “Buy”. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by Cowen & Co on Tuesday, September 12. The stock has “Buy” rating by Needham on Tuesday, June 13.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The company has market cap of $7.23 billion. The Company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus , as well as for the treatment of post-partum depression (PPD). It currently has negative earnings. The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus.

McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. The company has market cap of $31.35 billion. The firm operates in two divisions, McKesson Distribution Solutions and McKesson Technology Solutions. It has a 6.68 P/E ratio. The McKesson Distribution Solutions segment distributes branded and generic pharmaceutical drugs, and other healthcare-related products; and provides practice management, technology, clinical support, and business solutions to community oncology and other specialty practices.

Since September 7, 2017, it had 0 buys, and 5 insider sales for $121.68 million activity. Another trade for 65,000 shares valued at $10.40M was sold by HAMMERGREN JOHN H. Lampert Erin M sold $140,089 worth of stock or 900 shares.

The stock increased 1.56% or $2.33 during the last trading session, reaching $151.92. About 502,813 shares traded. McKesson Corporation (NYSE:MCK) has declined 15.45% since February 22, 2017 and is downtrending. It has underperformed by 32.15% the S&P500.

Investors sentiment decreased to 0.88 in 2017 Q3. Its down 0.07, from 0.95 in 2017Q2. It worsened, as 65 investors sold McKesson Corporation shares while 296 reduced holdings. 72 funds opened positions while 246 raised stakes. 180.04 million shares or 2.23% more from 176.11 million shares in 2017Q2 were reported. Guardian Life Insur Com Of America holds 0.01% of its portfolio in McKesson Corporation (NYSE:MCK) for 476 shares. Point72 Asset Lp has 45,000 shares. 404,415 were accumulated by Atlantic Gru Limited Liability Company. Vantage Invest Advisors Ltd Liability Co invested 0.01% in McKesson Corporation (NYSE:MCK). Butensky And Cohen Fincl Security holds 0.92% in McKesson Corporation (NYSE:MCK) or 6,738 shares. Raymond James & Associates owns 0.03% invested in McKesson Corporation (NYSE:MCK) for 109,659 shares. Fort Lp owns 2,120 shares. 21,264 are owned by Advantus Capital. Sg Americas Securities Ltd Co reported 0.02% stake. 3.50 million are held by Invesco. Kj Harrison Inc holds 7,000 shares or 0.37% of its portfolio. Orrstown Financial Ser Inc invested in 769 shares or 0.13% of the stock. Neumann Mngmt Limited Liability Company holds 0.48% or 5,085 shares in its portfolio. Brandes Prns Ltd Partnership, a California-based fund reported 730,251 shares. Denver Advsr Limited Co has invested 0.02% in McKesson Corporation (NYSE:MCK).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts